Novartis Presents Results of Beovu (brolucizumab -dbll) in P-III KESTREL and KITE Studies for Diabetic Macular Edema at ARVO2021
Shots:
- The company reported the 1yrs. results from the P-III KESTREL & KITE studies assessing Beovu (6mg) vs aflibercept (2mg) in 926 patients with DME across 36 countries
- Results: met its 1EPs i.e. non-inferiority in mean change BCVA from baseline @48wks.- patients treated with Beovu (6mg) experienced fluid (IRF/SRF) resolution and achieved CSFT levels below 280 μm @32 & 52 wks.- was well-tolerated safety in both studies
- Novartis is committed to bring Beovu (6mg) to DME patients and will submit the data from both trails to global health authorities in H1’21 while the company anticipates 2yrs. results in late 2021
Ref: PRnewswire | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com